ReviewJournal of clinical apheresis2020
Convalescent plasma therapy in patients with COVID-19.
Review in Journal of clinical apheresis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04642014 (A Multi-centre, 18-months, Single-group Study of Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease), which is not on this map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-centre, 18-months, Single-group Study of Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Metabolomic and Laboratory Evaluation of Plasma Therapy Effectiveness
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Convalescent plasma and all-cause mortality of COVID-19 patients: systematic review and meta-analysis.Scientific reports · 2023Pooled it
- Systematic review and meta-analysis of randomised controlled trials testing the safety and efficacy of convalescent plasma in the treatment of coronavirus disease 2019 (COVID-19): Evidence-base for practise and implications for research.Transfusion medicine (Oxford, England) · 2021Pooled it
- Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.JMIR public health and surveillance · 2021Pooled it
- Is there any potential management against COVID-19? A systematic review and meta-analysis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020Pooled it
- Therapeutic Plasma Exchange in Intensive Care Units-A 5-Year Multicenter Retrospective Study.Life (Basel, Switzerland) · 2025Article
- COVID-19 management in patients with comorbid conditions.World journal of virology · 2025Review
- Immunologic mediators profile in COVID-19 convalescence.Scientific reports · 2024Article
- Factors influencing plasma donation behavior of COVID-19 recovered patients in Bangladesh: A pilot study.Health science reports · 2023Article
- Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine.International immunopharmacology · 2022Review
- Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives.Stem cell research & therapy · 2022Review
- Neutralization effect of plasma from vaccinated COVID-19 convalescents on SARS-CoV-2 Omicron variants.Frontiers in immunology · 2022Article
- COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2021Article
- A novel nano therapeutic using convalescent plasma derived exosomal (CPChemico-biological interactions · 2021Article
- Stem cell therapy in coronavirus disease 2019: current evidence and future potential.Cytotherapy · 2021Review
- Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study.Annals of intensive care · 2021Article
- Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting.Inflammopharmacology · 2021Review
- Convalescent plasma therapy in patients with COVID-19.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2021Article
- Convalescent plasma therapy in patients with COVID-19.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2021Article
- COVID-19: Characteristics and Therapeutics.Cells · 2021Review
- Perplexing issues for convalescent immune plasma therapy in COVID-19.Northern clinics of Istanbul · 2021Review
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are currently no licensed vaccines or therapeutics for COVID-19. Anti-SARS CoV-2 antibody-containing plasmas, obtained from the recovered individuals who had confirmed COVID-19, have been started to be collected using apheresis devices and stored in blood banks in some countries in order to administer to the patients with COVID-19 for reducing the need of intensive care and the mortality rates. Therefore, in this review, we aim to point out some important issues related to convalescent plasma (CP) and its use in COVID-19. CP may be an adjunctive treatment option to the anti-viral therapy. The protective effect of CP may continue for weeks and months. After the assessment of the donor, 200-600 mL plasma can be collected with apheresis devices. The donation interval may vary between countries. Even though limited published studies are not prospective or randomized, until the development of vaccines or therapeutics, CP seems to be a safe and probably effective treatment for critically ill patients with COVID-19. It could also be used for prophylactic purposes but the safety and effectiveness of this approach should be tested in randomized prospective clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.